Comparison of Oxidative Stress Markers in Type 2 Diabetes: Basal Bolus Therapy versus Twice Daily Premixed Insulin Analogs

被引：3
|
作者：
Sakamoto, Masaki [1 ,2 ]
Inoue, Gaku [1 ,2 ]
Tsuyusaki, Kaoru [2 ]
Usui, Kensuke [2 ]
Watanabe, Miwako [3 ]
Irie, Junichiro [1 ,4 ]
Atsuda, Koichiro [2 ]
Yamada, Satoru [1 ,4 ]
机构：
[1] Kitasato Inst Hosp, Ctr Diabet, Tokyo, Japan
[2] Kitasato Univ, Sch Pharmaceut Sci, Dept Hosp Pharm, Tokyo 108, Japan
[3] Mareesia Garden Clin, Tokyo, Japan
[4] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan
来源：
INTERNAL MEDICINE | 2010年 / 49卷 / 05期
关键词：
oxidative stress; insulin therapy; diabetes; POSTPRANDIAL HYPERGLYCEMIA; DAILY INJECTIONS; COMPLICATIONS; HYPERINSULINEMIA; PREVALENCE; MELLITUS;
D O I：
10.2169/internalmedicine.49.2725
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Aims Several studies have shown that twice-daily injection of premixed insulin analog (MIX) therapy achieves glycemic control equivalent to that with basal-bolus (BB) therapy. However, glycemic fluctuations that lead to oxidative stress may be associated with the risk of diabetic complications. Therefore, in this study, we compared oxidative stress markers between MIX therapy and BB therapy. Methods In this cross-sectional study, we recruited a total of 37 patients (17 patients in the BB group and 20 patients in the MIX group) and compared urinary 8-isoprostane and urinary 8-hydroxydeoxyguanosine (8-OHdG) levels. Results There were no significant differences in urinary 8-isoprostane (BB vs MIX: 199 +/- 92 pg/mg Cr vs 266 +/- 107 pg/mg Cr) or urinary 8-OHdG (4.7 +/- 1.6 ng/mg Cr vs 5.4 +/- 1.9 ng/mg Cr, respectively). Conclusion These results suggest that MIX is equivalent to BB in terms of glycemic fluctuations and oxidative stress.
引用
收藏
页码：355 / 359
页数：5
相关论文
共 50 条
  • [31] Cost-utility analysis of once-weekly insulin icodec and once-daily insulin glargine in patients with type 2 diabetes receiving basal-bolus insulin therapy in China
    Dai, Nan
    Su, Xiaorong
    Wang, Yong
    DIABETES OBESITY & METABOLISM, 2025, 27 (01) : 377 - 386
  • [32] New therapeutic options for treating type-2 diabetes: A review of insulin analogs and premixed insulin analogs
    Choe, Charles
    Edelman, Steve
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2007, 99 (04) : 357 - +
  • [33] Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial
    Koivisto, V.
    Cleall, S.
    Pontiroli, A. E.
    Giugliano, D.
    DIABETES OBESITY & METABOLISM, 2011, 13 (12) : 1149 - 1157
  • [34] A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal-Bolus Therapy in Insulin-Naive Patients with Type 2 Diabetes
    Linjawi, Sultan
    Lee, Byung-Wan
    Tabak, A-mur
    Lovdahl, Susanna
    Werther, Shanti
    Abusnana, Salahedeen
    DIABETES THERAPY, 2018, 9 (01) : 1 - 11
  • [35] People with Type 2 Diabetes on Premixed Insulin Therapy: How is the Daily Insulin Dose Partitioned and are there Effects on the Metabolic Control?
    Roth, J.
    Milke, B.
    Mueller, N.
    Zitterbart, U.
    Rechtacek, S.
    Rechtacek, T.
    Kloos, C.
    Wolf, G.
    Mueller, U. A.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2015, 123 (06) : 368 - 370
  • [36] Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes
    Raslová, K
    Bogoev, M
    Raz, I
    Leth, G
    Gall, MA
    Hancu, N
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) : 193 - 201
  • [37] Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study
    Umpierrez, Guillermo
    Gill, Jasvinder
    Hood, David
    Li, Xuan
    Nunez, Ana
    DIABETES OBESITY & METABOLISM, 2024, : 795 - 805
  • [38] Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin
    Blak, B. T.
    Smith, H. T.
    Hards, M.
    Curtis, B. H.
    Ivanyi, T.
    DIABETIC MEDICINE, 2012, 29 (07) : E13 - E20
  • [39] Differences in metabolic effects of twice daily versus multiple daily insulin injections in children with type 1 diabetes
    Abid, Noina
    Porter, Lesley
    Day, Emma
    Krone, Nils
    Hoegler, Wolfgang
    Kirk, Jeremy
    Shaw, Nick
    Barrett, Tim
    PRACTICAL DIABETES, 2011, 28 (09) : 384 - 387
  • [40] Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
    Rosenstock, Julio
    Guerci, Bruno
    Hanefeld, Markolf
    Gentile, Sandro
    Aronson, Ronnie
    Tinahones, Francisco J.
    Roy-Duval, Christine
    Souhami, Elisabeth
    Wardecki, Marek
    Ye, Jenny
    Perfetti, Riccardo
    Heller, Simon
    DIABETES CARE, 2016, 39 (08) : 1318 - 1328
12345